Canaccord Genuity Remains Bullish on Heartware (HTWR) Following Agreement to Acquire Valtech Cardio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 09/02: (SURG) (VRA) (WMGI) Higher; (RJET) (DGLY) (HTWR) Lower (more...)
September 2, 2015 9:23 AM EDTA listing of stocks moving in the pre market trading session:
Synergetics USA, Inc. (NASDAQ: SURG) 53% HIGHER; Synergetics USA and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments... More
Heartware International's (HTWR) Valtech Cardio Acquisition Doesn't Make Sense, Says Northland
September 2, 2015 9:18 AM EDTNorthland Capital Markets maintained an Underperform rating on Heartware International (NASDAQ: HTWR) with a price target of $60. Analyst Suraj Kalia said the company's acquisition of Valtech Cardio does not makes sense.
Kalia explained, "Valtech is a pre-revenue company developing surgical & transcatheter mitral repair / replacement... More
Raymond James Downgrades Heartware (HTWR) to Market Perform
September 2, 2015 8:36 AM EDTRaymond James downgraded Heartware Int'l (NASDAQ: HTWR) from Outperform to Market Perform and removed its price target (prior $102.00).
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $81.81 yesterday.
... MoreBTIG Downgrades Heartware Int'l (HTWR) to Neutral
September 2, 2015 8:13 AM EDTBTIG downgraded Heartware Int'l (NASDAQ: HTWR) from Buy to Neutral. The change follows its acquisition of Valtech.
"While we understand the rationale of this acquisition and it may prove to be a strong asset over the next 3-5 years, we anticipate there... More
Heartware (HTWR) to Acquire Valtech Cardio
September 1, 2015 4:25 PM EDTHeartware (NASDAQ: HTWR) announced today that it has entered into a definitive agreement to acquire Valtech Cardio, Ltd. ("Valtech"). Valtech is a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases mitral valve regurgitation (MR) and... More
